Client First Investment Management LLC purchased a new position in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 61,321 shares of the company’s stock, valued at approximately $2,579,000. ARK Genomic Revolution ETF makes up 1.1% of Client First Investment Management LLC’s holdings, making the stock its 16th largest position.
Other institutional investors have also modified their holdings of the company. Ascentis Independent Advisors purchased a new stake in shares of ARK Genomic Revolution ETF in the 1st quarter valued at $26,000. PNC Financial Services Group Inc. boosted its holdings in ARK Genomic Revolution ETF by 53.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock valued at $29,000 after acquiring an additional 378 shares during the period. Sunbelt Securities Inc. boosted its holdings in ARK Genomic Revolution ETF by 734.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock valued at $31,000 after acquiring an additional 984 shares during the period. Western Wealth Management LLC acquired a new position in ARK Genomic Revolution ETF in the 1st quarter valued at about $37,000. Finally, Strategic Wealth Investment Group LLC acquired a new position in ARK Genomic Revolution ETF in the 2nd quarter valued at about $38,000.
ARK Genomic Revolution ETF Trading Up 6.1%
Shares of BATS:ARKG opened at $43.04 on Friday. The firm’s 50-day moving average is $38.55 and its two-hundred day moving average is $32.47. ARK Genomic Revolution ETF has a 1 year low of $23.20 and a 1 year high of $44.47.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Read More
- Five stocks we like better than ARK Genomic Revolution ETF
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
